Efficacy and safety of immune checkpoint inhibitors for hepatocellular carcinoma patients with macrovascular invasion or extrahepatic spread: a systematic review and meta-analysis of 54 studies with 6187 hepatocellular carcinoma patients

[1] Sung H(2021)Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 71 209-249

[2] Ferlay J(2021)Hepatocellular carcinoma Nat Rev Dis Primers 7 6-528

[3] Siegel RL(2018)Defining the most appropriate primary end point in phase 2 trials of immune checkpoint inhibitors for advanced solid cancers: a systematic review and meta-analysis JAMA Oncol 4 522-249

[4] Laversanne M(2021)Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance Annu Rev Pathol 16 223-788

[5] Soerjomataram I(2019)The role of the lymphocyte functional crosstalk and regulation in the context of checkpoint inhibitor treatment-review Front Immunol 10 2043-406

[6] Jemal A(2020)Precision medicine: steps along the road to combat human cancer Cells 13 827-S132

[7] Llovet JM(2022)The predictive potential of the baseline C-reactive protein levels for the efficiency of immune checkpoint inhibitors in cancer patients: a systematic review and meta-analysis Front Immunol 10 404-605

[8] Kelley RK(2021)Role of liver resection for hepatocellular carcinoma with vascular invasion: emerging evidence from western countries Liver Cancer 127 S126-1055

[9] Villanueva A(2004)Diagnosis and staging of hepatocellular carcinoma Gastroenterology 13 66-6994

[10] Singal AG(2021)Survival benefit of hepatic arterial infusion chemotherapy over sorafenib in the treatment of locally progressed hepatocellular carcinoma Cancers 339 e2535-e261

[1] Sung H(2021)Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 71 209-249

[2] Ferlay J(2021)Hepatocellular carcinoma Nat Rev Dis Primers 7 6-528

[3] Siegel RL(2018)Defining the most appropriate primary end point in phase 2 trials of immune checkpoint inhibitors for advanced solid cancers: a systematic review and meta-analysis JAMA Oncol 4 522-249

[4] Laversanne M(2021)Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance Annu Rev Pathol 16 223-788

[5] Soerjomataram I(2019)The role of the lymphocyte functional crosstalk and regulation in the context of checkpoint inhibitor treatment-review Front Immunol 10 2043-406

[6] Jemal A(2020)Precision medicine: steps along the road to combat human cancer Cells 13 827-S132

[7] Llovet JM(2022)The predictive potential of the baseline C-reactive protein levels for the efficiency of immune checkpoint inhibitors in cancer patients: a systematic review and meta-analysis Front Immunol 10 404-605

[8] Kelley RK(2021)Role of liver resection for hepatocellular carcinoma with vascular invasion: emerging evidence from western countries Liver Cancer 127 S126-1055

[9] Villanueva A(2004)Diagnosis and staging of hepatocellular carcinoma Gastroenterology 13 66-6994

[10] Singal AG(2021)Survival benefit of hepatic arterial infusion chemotherapy over sorafenib in the treatment of locally progressed hepatocellular carcinoma Cancers 339 e2535-e261